Immunotherapy for the Urologist: Basic Principles, Adverse Effects & Drug Delivery Webcast 019IC (2018)

The goal of the course is to provide both a basic and real-world application of immunotherapy for genitourinary oncology. The course is directed towards the urologist with an interest, but no prior experience delivering immunotherapy agents to patients with bladder and kidney cancer (with possible application to prostate cancer in the future). Starting with innovating breakthroughs, new therapies and their side-effects, the course will also cover common side-effects and biomarkers to risk stratify patients. We will plan to discuss real world-challenges in starting an immunotherapy program, from regulatory requirements to coding and billing for systemic therapies.


This educational series is supported by independent educational grants from:

  • AstraZeneca
  • Genentech
  • Merck & Co., Inc.

Target Audience

  • Urologist
  • Resident
  • Advanced Practice Provider (Nurse Practitioners & Physician Assistants)

Learning Objectives

After completing this activity, participants will be able to:

  1. Describe the new innovations in tumor immunology and new immunotherapies in order to identify right drug for the right patient.
  2. Summarize the major findings in bladder and kidney cancer trials using immunotherapy.
  3. Define the non-immune and the immune related side effects and to manage the common side effects of immunotherapy.
  4. Discuss the implementation of a systemic immunotherapy program in your practice, including regulatory, billing and coding for immunotherapy treatment
  5. Identify predictive biomarkers of immuno-oncology treatment
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
Course expires: 

Course Director:
Joshua Meeks, MD, PhD: National Comprehensive Cancer Network- Prostate Cancer Guidelines Committee: Other; Veteran's Health Administration: Scientific Study or Trial; Merck: Scientific Study or Trial; Merck: Consultant or Advisor; Prostate Cancer Foundation: Other; John Hanson Research Foundation: Other;  Epizyme: Other; AbbVie: Other; Tesaro: Other; NextCure: Scientific Study or Trial; NCI: Scientific Study or Trial, Other

Course Faculty: 
Peter Black, MD, FACS, FRCSC: 
GenomeDx Biosciences Inc: Consultant or Advisor, Scientific Study or Trial; Janssen: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Astellas: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Amgen: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Sitka: Consultant or Advisor; AbbVie: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Bristol Myers Squibb: Consultant or Advisor; UroGen: Consultant or Advisor; European Urology Focus: Health Publishing; PLOS ONE: Health Publishing; BMC Urology: Health Publishing; Merck: Consultant or Advisor; iProgen: Scientific Study or Trial; Bayer: Consultant or Advisor; Biosyent: Consultant or Advisor; RedLeaf Medical: Meeting Participant or Lecturer; Biocancell: Consultant or Advisor; Roche/Genentech: Consultant or Advisor, Scientific Study or Trial; World Journal of Urology: Health Publishing; Urologic Oncology: Health Publishing; Bladder Cancer: Health Publishing

Neal Shore, MD, FACS:Terence Friedlander, MD: GP Pharma: Consultant or Advisor; Astellas: Consultant or Advisor; dendreon: Consultant or Advisor; Janssen: Consultant or Advisor; Bayer: Consultant or Advisor; MyriadL: Consultant or Advisor; Pfizer: Consultant or Advisor, Scientific Study or Trial; Pfizer: Consultant or Advisor, Scientific Study or Trial; emdSeronoMerck: Consultant or Advisor; AstraZeneca: Consultant or Advisor, Scientific Study or Trial; Merck: Consultant or Advisor, Scientific Study or Trial; Astra Zeneca: Consultant or Advisor, Scientific Study or Trial; Genentech: Scientific Study or Trial; Genomic Health: Consultant or Advisor; MDxHealth: Consultant or Advisor; Tolmar: Consultant or Advisor, Scientific Study or Trial; Moivant: Consultant or Advisor, Scientific Study or Trial; Spectrum: Consultant or Advisor, Scientific Study or Trial; Pacific Edge: Consultant or Advisor, Scientific Study or Trial

Brian Shuch, MD: Nothing to Disclose

Kelly Stratton, MD: Ebix: Other; Bayer Corporation: Consultant or Advisor; MDXHealth: Consultant or Advisor; Oakstone: Other

Robert Svatek, MD: Japanese BCG Laboratories: Scientific Study or Trial; Rapamycin Holdings: Consultant or Advisor; GenomeDx: Scientific Study or Trial; MDxHealth: Consultant or Advisor; MDxHealth: Consultant or Advisor; MDxHealth: Consultant or Advisor

Method of Participation
To claim CME credit/hours of participation, the learner must view the webcast, complete the post-test passing with 80% accuracy and submit the activity evaluation.
Estimated time to complete this activity: 2.00 hour
Release Date: June, 2018
Expiration Date: June, 2019

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation: The American Urological Association designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1.00 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

This educational activity is supported by independent educational grants from AbbVie, Astellas, Genomic Health, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Medivation, Inc. a Pfizer company, Sanofi Genzyme, AstraZeneca, Genentech and Merck & Co., Inc.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Please login or register to take this course.